NO.: ISRT-0327/RTS-0327

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

JUN 1 3 2003

TECH CENTER 1600/2900 OOCKET NO.: ISRT-0327/RTS-0327

In Re Application of:

Brenda F. Baker, et al.

Application No.: 10/000,213

Filing Date: November 14, 2001

ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR **EXPRESSION**

Examiner: Terra C. Gibbs

EXPRESS MAIL LABEL NO: EV251284338US DATE OF DEPOSIT: June 9, 2003

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

> In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of request				
	continued examination under § 1.114, no additional fee is required.				
	In accordance with § 1.129(a), this Information Disclosure Statement is being				
	filed in connect	ion with the first or second After Final Submission,			
	therefore:				
		ertification in Accordance with § 1.97(e) is attached; or			
	П	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.			
\boxtimes	In accordance v	with § 1.97(c), this Information Disclosure Statement is being			
	filed after the period set forth in § 1.97(b) above but before the mailing date of				
	either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or				
	before an action that otherwise closes prosecution in the application, therefore:				
	\boxtimes	Certification in Accordance with § 1.97(e) is attached;			
		or			
		The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.			
	In accordance with § 1.97(d), this Information Disclosure Statement is being				
	filed after the mailing date of either a Final Action under § 1.113 or a Notice				
	of Allowance under § 1.311 but before, or simultaneously with, the payment				
	of the Issue Fee, therefore included are: Certification in Accordance with §				
	1.97(e); and the submission fee of $$180.00$ as set forth in $$1.17(p)$.				
\boxtimes	Copies of each	of the references listed on the attached Form PTO-1449 are			
	enclosed herewith.				

DOCKET NO.: ISRT-0327/RTS-0327 - 3 - PATENT

Copie	s of references listed on the attached Form PTO-1449 are enclosed			
herewith				
EXCE	PT THAT:			
	In view of the voluminous nature of references [list as appropriate],			
	and the likelihood that these references are available to the Examiner,			
	copies are not enclosed herewith.			
	In accordance with § 1.98(d), copies of the following references listed			
	on the attached Form PTO-1449 are not enclosed herewith because			
	they were previously cited by or submitted to the U.S. Patent and			
	Trademark Office in patent application(s) for which a claim for priority			
	under 35 U.S.C.§ 120 have been made in the instant application:			
	Copies of references [list as appropriate] listed on the attached Form			
	PTO-1449 were previously cited by or submitted to the Patent and			
	Trademark Office in prior Application No. , filed .			
	If any of the foregoing publications are not available to the			
	Examiner, Applicant will endeavor to supply copies at the			
	Examiner's request			

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated May 7, 2003

(Number 19 on the PTO-1449), which indicates the references considered to be relevant.

There are no listed references which are not in the English language.

Date: 6/9/03

Phillip A. Singer

Registration No. 40,176

WOODCOCK WASHBURN LLP

One Liberty Place - 46th Floor

Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

← 2003 WW



EXAMINER

Sheet 1 of 2

		PTO-1449 Modified	Docket No. ISRT-0327/ RTS-0327	Application No. 10/000,2131ECF/1/2		
(U	Jse se	Patent and Publications Cited by Applicant veral sheets if necessary)	Application No. 15RT-0327/ RTS-0327 Applicant Brenda F. Baker, et al. Filing Date Group November 14, 2001 1635			
	U.S. Department of Commerce Patent and Trademark Office			Group 1635		
O	гнен	R DOCUMENTS (Including Author,	Title, Date, Pertinent	Pages, Etc.)		
	19	Copy of the PCT International Search	Report dated May 7, 2	2003 (PCT/US02/36692)		
•	20	Branch, A.D., "A good antisense mol 45-50	lecule is hard to find," T	TIBS, February 1998 , 23,		
	21	Fritz, H., et al., "Cationic polystyrene of a model drug carrier system for an <i>Interface Science</i> , 1997 , <i>195</i> , 272-28	tisense oligonucleotides	s," J. of Colloid and		
,	22	Jen, K-Y., et al., "Suppression of gen messenger RNA: available options at www.StemCells.com, 2000, 18, 307	nd current strategies," S			
	23	Weintraub, H.M., et al., "Antisense R 1990, 40-46	NA and DNA," Scienti	fic American, January		

DATE CONSIDERED



Sheet 2 of 2

Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docket No.
ISRT-0327/
RTS-0327

Applicant

Brenda F. Baker, et al.

Application NRECE/VED
10/000,213 RECE/VED

JUN 1 3 2003
TECH CENTER 1600/2900

Filing Date November 14, 2001 1635

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	24	5,801,154	09/01/98	Baracchini, et al.	514	44
				1		
		FOR	EIGN PATEN	T DOCUMENTS		
Examiner					Tra	anslation
Initial		Document No.	Date	Country	YES	NO
•						-
					- 1	

,		
	EXAMINER	DATE CONSIDERED